ViaLase

Executive Summary

ViaLase is a privately held medical device company headquartered in Irvine, California, pioneering a novel femtosecond laser system for the treatment of glaucoma. Founded in 2017, the company aims to address the limitations of current glaucoma therapies by creating precise, noninvasive apertures in the eye's natural drainage pathway to lower intraocular pressure without incisions. This approach has the potential to offer a safer, more reproducible, and less invasive alternative to traditional surgical interventions such as trabeculectomy or tube shunts. ViaLase is currently in the Phase 1 clinical stage, evaluating the safety and feasibility of its technology in early-stage glaucoma patients. The company's technology is backed by a strong intellectual property portfolio and has garnered interest from key opinion leaders in ophthalmology. While still in early development, ViaLase represents a promising shift toward minimally invasive glaucoma surgery (MIGS) with a unique laser-based mechanism. Success in ongoing trials could position the company as a leader in the next generation of glaucoma care, addressing a large and growing global patient population. Near-term focus is on completing initial clinical studies and securing regulatory clearance to advance to pivotal trials.

Upcoming Catalysts (preview)

• Q4 2026Phase 1 clinical data readout70% success
• Q2 2027FDA IDE approval for pivotal trial60% success
• Q1 2027Series B or C financing round80% success